Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy
暂无分享,去创建一个
C. Langmead | F. Marshall | M. Weir | C. Tate | G. Lebon | B. Tehan | K. Bennett
[1] A. IJzerman,et al. Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time , 2012, British journal of pharmacology.
[2] T. Höfer,et al. Constitutive activity of the A2A adenosine receptor and compartmentalised cyclic AMP signalling fine-tune noradrenaline release , 2012, Purinergic Signalling.
[3] Nathan Robertson,et al. Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .
[4] Jonathan S. Mason,et al. Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.
[5] P. Sexton,et al. A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation* , 2011, The Journal of Biological Chemistry.
[6] M. Congreve,et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.
[7] Nathan Robertson,et al. Biophysical Mapping of the Adenosine A2A Receptor , 2011, Journal of medicinal chemistry.
[8] C. Tate,et al. Thermostabilisation of an Agonist-Bound Conformation of the Human Adenosine A2A Receptor , 2011, Journal of molecular biology.
[9] A. Leslie,et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.
[10] Nathan Robertson,et al. The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.
[11] J. Salamone. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders. , 2010, IDrugs : the investigational drugs journal.
[12] A. Pinna. Novel investigational adenosine A2A receptor antagonists for Parkinson's disease , 2009, Expert opinion on investigational drugs.
[13] C. Tate,et al. Engineering G protein-coupled receptors to facilitate their structure determination. , 2009, Current opinion in structural biology.
[14] Yoko Shibata,et al. Thermostabilisation of the neurotensin receptor NTS1 , 2009, Journal of molecular biology.
[15] Gebhard F. X. Schertler,et al. Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.
[16] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[17] Richard R. Neubig,et al. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List , 2005, Pharmacological Reviews.
[18] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[19] J. Linden,et al. Cyclic AMP‐dependent inhibition of human neutrophil oxidative activity by substituted 2‐propynylcyclohexyl adenosine A2A receptor agonists , 2001 .
[20] J. Linden,et al. Design, synthesis, and evaluation of novel A2A adenosine receptor agonists. , 2001, Journal of medicinal chemistry.
[21] A. IJzerman,et al. Inverse agonism at G protein‐coupled receptors: (patho)physiological relevance and implications for drug discovery , 2000, British journal of pharmacology.
[22] P. Strange. Agonist binding to G‐protein coupled receptors , 2000, British journal of pharmacology.
[23] P. Svenningsson,et al. Dopamine–Adenosine Interactions in the Striatum and the Globus Pallidus: Inhibition of Striatopallidal Neurons through Either D2 or A2A Receptors Enhances D1Receptor-Mediated Effects on c-fos Expression , 1997, The Journal of Neuroscience.
[24] H. Jüppner,et al. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. , 1995, Science.
[25] P. Leff,et al. The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.
[26] R. Lefkowitz,et al. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.
[27] R. Lefkowitz,et al. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.
[28] Vadim Cherezov,et al. Diversity and modularity of G protein-coupled receptor structures. , 2012, Trends in pharmacological sciences.
[29] B. Fredholm,et al. Adenosine and the regulation of metabolism and body temperature. , 2011, Advances in pharmacology.
[30] J. Linden,et al. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. , 2001, British journal of pharmacology.
[31] R. Graham,et al. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. , 1996, Molecular pharmacology.
[32] R. Lefkowitz,et al. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. , 1980, Molecular pharmacology.